Our partnering approach

  • Ultragenyx seeks partners aligned with the company’s core values and vision for developing and bringing transformative therapies to those living with rare and ultrarare disease worldwide
  • We are dedicated to addressing the needs of those living with rare and ultrarare disease, as demonstrated by our core values and as implemented through our Dynamic Development Model
  • We have a flexible partnering approach to enable rare disease product development and commercialization
  • Our flexible partnering model allows us to collaborate broadly with academics and biopharma industry partners in developing rare disease therapeutics or platform technologies. It can be tailored to development stage, regional rights, or other unique requirements
  • The key to our combined success is to operate in the best interest of patients and the product


Relentless Icon

We won’t give up fighting for our patients
Always searching for solutions together


Possibility Icon

We seek the undiscovered discoveries
We’re committed to finding options for those who have none


Bulb Icon

We learn and adapt
Constantly searching for deeper understanding and rapidly evolving our plans based on our insights

Team execution and focus on long-term value creation

  • Close collaboration between Search & Evaluation, Transactions, and Alliance Management allows seamless transition from sourcing new external opportunities to conducting due diligence, closing deals, and kicking off collaborations
  • Alliance Management oversees partnering lifecycle, monitors health of alliances to ensure collaboration goals remain on track, and works closely and effectively with internal stakeholders and external partners. These ensure that all parties are meeting contractual obligations while fostering ongoing collaboration to maximize value for the partnership

Areas of interest

Focus Areas AOI

Rare disease therapies by design

Clear biology
Transformative rare/ultrarare therapies

Development AOI

Dynamic development
and commercial model

Unique trial and endpoint design
Rapid development
Internal process development
Expanded access programs
Broad commercial presence

Diverse Modalities AOI

Diverse modalities

Gene therapy
Small molecule
Protein biologics

Therapies by design AOI

Therapeutic focus areas


Collaborations and partnerships

Abeona Therapeutics logo
Arcturus Therapeutics logo
Baylor Scott & White Health logo
Daiichi-Sankyo logo
Mereo BioPharma logo
Penn - University of Pennsylvania logo
Regeneron logo
Saint Louis University SLU logo
Solid Biosciences logo
Texas A&M University logo

Contact us for partnerships

We are interested in hearing from people who are focused on improving the lives of those living with serious rare and ultrarare genetic diseases.

To inquire about how to partner with Ultragenyx,
contact our Business Development team at [email protected].